PreprintCited by 65Computational Drug Discovery MethodsBioinformatics and Genomic NetworksBiomedical Text Mining and Ontologies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

DTSyn: a dual-transformer-based neural network to predict synergistic drug combinations

Open access

Preprint — published as 10.1093/bib/bbac302 · Paper page

Abstract

Drug combination therapies are superior to monotherapy for cancer treatment in many ways when addressing tumor heterogeneity issue. For wet-lab experiment, screening out novel synergistic drug pairs is challenging due to the enormous searching space of possible drug pairs. Thus, computational methods have been developed to predict drug pairs with potential synergistic function. Notwithstanding the success of current models, the power of generalization to other datasets as wells as understanding of mechanism for chemical-chemical interaction or chemical-sample interaction are lack of study, hindering current algorithms from real application. In this paper, we proposed a deep neural model termed DTSyn (Dual Transformer model for drug pair Synergy prediction) based on multi-head attention mechanism to identify novel drug combinations. We designed a fine-granularity transformer for capturing chemical substructure-gene and gene-gene associations and a coarse-granularity transformer for extracting chemical-chemical and chemical-cell line interactions. DTSyn achieves highest Receiver operating characteristic area under curve (ROC AUC) of 0.73, 0.78. 0.82 and 0.81 on four different cross validation tasks, outperforming all competing methods. Further, DTSyn achieved best True Positive Rate (TPR) over five independent datasets. The ablation study showed that both transformer blocks contributed to the performance of DTSyn. In addition, DTSyn can extract interactions among chemicals and cell lines, which may represent the mechanisms of drug action. Thus, we envision our model a valuable tool to prioritize synergistic drug pairs by utilizing chemicals and transcriptome data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.03.29.486200

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. 10.1023/A:1010933404324 · DOI · Paper page
  2. 2018, Overexpression of the recently identified oncogene redd1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma, Diagnostic pathology, 13, 1
  3. 2016, Systematic quality control analysis of lincs data, CPT: pharmacometrics & systems pharmacology, 5, 588
  4. 10.1124/pr.58.3.10 · DOI · Paper page
  5. 2022, p53-mediated akt and mtor inhibition requires rfx7 and ddit4 and depends on nutrient abundance, Oncogene, 41, 1063, 10.1038/s41388-021-02147-z · DOI
  6. 10.2174/156802607781696864 · DOI
  7. 10.1186/s13046-018-0683-9 · DOI
  8. M. d. F. D. de Souza , A. F. da Silva Filho , A. P. de Barros Albuquerque , M. W. L. Quirino , M. S. de Souza Albuquerque , M. F. Cordeiro , M. R. Martins , I. da Rocha Pitta , A. R. Lucena-Araujo , M. G. da Rocha Pitta , et al. Overexpression of udp-glucose 4-epimerase is associated with differentiation grade of gastric cancer. Disease markers, 2019, 2019. · DOI
  9. 2019, Statistical determination of synergy based on bliss definition of drugs independence, PLoS One, 14, e0224137, 10.1371/journal.pone.0224137 · DOI · Paper page
  10. 2021, High expression of dna damage-inducible transcript 4 (ddit4) is associated with advanced pathological features in the patients with colorectal cancer, Scientific Reports, 11, 1
  11. 2019, A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines, Scientific Data, 6, 1
  12. 2017, Systematic quantification of population cell death kinetics in mammalian cells, Cell systems, 4, 600, 10.1016/j.cels.2017.05.002 · DOI
  13. 10.1006/jcss.1997.1504 · DOI · Paper page
  14. 10.1038/s41586-019-1186-3 · DOI · Paper page
  15. 2015, A new drug combinatory effect prediction algorithm on the cancer cell based on gene expression and dose–response curve, CPT: pharmacometrics & systems pharmacology, 4, 80
  16. A. Grover and J. Leskovec . node2vec: Scalable feature learning for networks. In Proceedings of the 22nd ACM SIGKDD international conference on Knowledge discovery and data mining, pages 855–864, 2016. · DOI · Paper page
  17. 2021, Dti-voodoo: machine learning over interaction networks and ontology-based background knowledge predicts drug–target interactions, Bioinformatics, 37, 4835, 10.1093/bioinformatics/btab548 · DOI
  18. 1998, Snap-25, The international journal of biochemistry & cell biology, 30, 1069, 10.1016/S1357-2725(98)00079-X · DOI
  19. 10.1158/0008-5472.CAN-17-0489 · DOI · Paper page
  20. 2017, Detection of lower levels of snap25 using multiple microarray systems and its functional significance in medulloblastoma, International Journal of Molecular Medicine, 39, 1195, 10.3892/ijmm.2017.2925 · DOI
  21. 2020, Deep graph embedding for prioritizing synergistic anticancer drug combinations, Computational and structural biotechnology journal, 18, 427, 10.1016/j.csbj.2020.02.006 · DOI
  22. 2011, Redd1 inhibits the invasiveness of non-small cell lung cancer cells, Biochemical and biophysical research communications, 407, 507, 10.1016/j.bbrc.2011.03.047 · DOI
  23. W. Jin , J. M. Stokes , R. T. Eastman , Z. Itkin , A. V. Zakharov , J. J. Collins , T. S. Jaakkola , and R. Barzilay . Deep learning identifies synergistic drug combinations for treating covid-19. Proceedings of the National Academy of Sciences, 118(39), 2021. · DOI
  24. 2016, Semi-supervised classification with graph convolutional networks, arXiv preprint
  25. 2019, Synergistic inhibition of mek and reciprocal feedback networks for targeted intervention in malignancy, Cancer Biology & Medicine, 16, 415, 10.20892/j.issn.2095-3941.2019.0137 · DOI
  26. 10.1158/1078-0432.CCR-11-3321 · DOI
  27. W. Lin , L. Wu , Y. Zhang , Y. Wen , B. Yan , C. Dai , K. Liu , S. He , and X. Bo . An enhanced cascade-based deep forest model for drug combination prediction. Briefings in Bioinformatics, 2022. · DOI
  28. 1953, The problem of synergism and antagonism of combined drugs, Arzneimittelforschung, 3, 285
  29. 2019, Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer, PLoS computational biology, 15, e1006752, 10.1371/journal.pcbi.1006752 · DOI
  30. 2018, Umap: Uniform manifold approximation and projection for dimension reduction, arXiv preprint
  31. 10.1038/s41467-019-08856-0 · DOI
  32. 2013, Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mtor signaling, Translational oncology, 6, 649, 10.1593/tlo.13556 · DOI · Paper page
  33. 2016, Systematic analysis of quantitative logic model ensembles predicts drug combination effects on cell signaling networks, CPT: pharmacometrics & systems pharmacology, 5, 544
  34. 2018, Stx3 represses the stability of the tumor suppressor pten to activate the pi3k-akt-mtor signaling and promotes the growth of breast cancer cells, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1864, 1684, 10.1016/j.bbadis.2018.01.031 · DOI
  35. 10.1038/nbt1206-1565 · DOI
  36. 10.1158/1535-7163.MCT-15-0843 · DOI · Paper page
  37. 10.1093/nar/gky1079 · DOI
  38. N. Parmar , A. Vaswani , J. Uszkoreit , L. Kaiser , N. Shazeer , A. Ku , and D. Tran . Image transformer. In International Conference on Machine Learning, pages 4055–4064. PMLR, 2018.
  39. 10.1158/1535-7163.MCT-10-0324 · DOI
  40. 2021, A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to covid-19 drug repurposing, Nature machine intelligence, 3, 247, 10.1038/s42256-020-00285-9 · DOI
  41. 2018, Deepsynergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI
  42. 2013, Repositioning metformin for cancer prevention and treatment, Trends in Endocrinology & Metabolism, 24, 469, 10.1016/j.tem.2013.05.004 · DOI
  43. 10.1158/1535-7163.MCT-10-0792 · DOI
  44. 2020, Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting cdk2/5/9, Scientific reports, 10, 1
  45. 10.1038/sj.onc.1208236 · DOI
  46. 10.1038/nrd.2016.29 · DOI · Paper page
  47. 2009, Vorinostat in solid and hematologic malignancies, Journal of hematology & oncology, 2, 1
  48. 10.1016/j.cell.2017.10.049 · DOI · Paper page
  49. 2019, Gale promotes the proliferation and migration of glioblastoma cells and is regulated by mir-let-7i-5p, Cancer Management and Research, 11, 10539, 10.2147/CMAR.S221585 · DOI
  50. 2020, Dtf: Deep tensor factorization for predicting anticancer drug synergy, Bioinformatics, 36, 4483, 10.1093/bioinformatics/btaa287 · DOI
  51. 2018, Dna damage inducible transcript 4 gene: the switch of the metabolism as potential target in cancer, Frontiers in oncology, 8, 106, 10.3389/fonc.2018.00106 · DOI
  52. A. Vaswani , N. Shazeer , N. Parmar , J. Uszkoreit , L. Jones , A. N. Gomez , L-. Kaiser , and I. Polosukhin . Attention is all you need. Advances in neural information processing systems, 30, 2017.
  53. 10.1074/jbc.275.4.2959 · DOI
  54. 2015, Tgf-β regulates the proliferation of lung adenocarcinoma cells by inhibiting pik3r3 expression, Molecular Carcinogenesis, 54, E162
  55. 2022, Deepdds: deep graph neural network with attention mechanism to predict synergistic drug combinations, Briefings in Bioinformatics, 23, bbab390, 10.1093/bib/bbab390 · DOI
  56. 10.1021/ci00057a005 · DOI · Paper page
  57. T. Wolf , L. Debut , V. Sanh , J. Chaumond , C. Delangue , A. Moi , P. Cistac , T. Rault , R. Louf , M. Funtowicz , et al. Transformers: State-of-the-art natural language processing. In Proceedings of the 2020 conference on empirical methods in natural language processing: system demonstrations, pages 38–45, 2020. · DOI · Paper page
  58. 2015, Searching for drug synergy in complex dose–response landscapes using an interaction potency model, Computational and structural biotechnology journal, 13, 504, 10.1016/j.csbj.2015.09.001 · DOI · Paper page
  59. 10.1038/s41419-021-03614-x · DOI
  60. L. Yuan , Y. Chen , T. Wang , W. Yu , Y. Shi , Z.-H. Jiang , F. E. Tay , J. Feng , and S. Yan . Tokens-to-token vit: Training vision transformers from scratch on imagenet. In Proceedings of the IEEE/CVF International Conference on Computer Vision, pages 558–567, 2021. · DOI · Paper page
  61. 10.1093/nar/gkz337 · DOI
  62. 10.1158/1078-0432.CCR-17-0419 · DOI
  63. 2017, Prkcd/pkcδ contributes to nephrotoxicity during cisplatin chemotherapy by suppressing autophagy, Autophagy, 13, 631, 10.1080/15548627.2016.1269990 · DOI
  64. 2018, Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo, Oncology Letters, 15, 1811
  65. 2017, Recent advances in the use of pi3k inhibitors for glioblastoma multiforme: current preclinical and clinical development, Molecular cancer, 16, 1
  66. 2015, Phase i study of the mtor inhibitor ridaforolimus and the hdac inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors, Investigational new drugs, 33, 1040, 10.1007/s10637-015-0261-3 · DOI
  67. 10.1111/j.1467-9868.2005.00503.x · DOI · Paper page

Metadata

Authors
Hu, J., Gao, J., Fang, X., Liu, Z., Wang, F., Huang, W., wu, H., & Zhao, G.
Affiliations
Baidu (China) (CN)
Corresponding author
Zhao, Guodong
Venue
Briefings in Bioinformatics
Publisher
openRxiv
Published
2022-03-30
Volume
23
Issue
5
ISSN
1467-5463 (ISSN-L)
OpenAlex
W4289315841
Cited by
65
References
1
Citations by year
2026: 9 · 2025: 35 · 2024: 12 · 2023: 8 · 2022: 1
FWCI
7.58
Type
journal article
Language
en
Open access
Locations
  • Briefings in Bioinformatics (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
Keywords
drug synergy prediction, synergistic drug combination, multi-head attention, combination cancer therapy, chemical-gene interactions, gene-gene interaction, gene embeddings, interpretability
MeSH terms
Algorithms, Drug Combinations, ROC Curve, Neural Networks, Computer, Computational Biology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review